GlassScriptPhysician profile
Haley Anne Bywaters
NPI 1801540034
$2,160.82
in general payments reported to CMS, 2019-2025
41 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $352 · 2023: $727 · 2024: $825 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.01 |
| Education | $299.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $263.72 | 2023-2024 | Padcev, Xospata |
| Janssen Biotech, INC. | $238.29 | 2022-2024 | Rybrevant, Tecvayli, Talvey |
| Genentech USA, INC. | $171.28 | 2022-2025 | Tecentriq, Venclexta, Perjeta |
| Novartis Pharmaceuticals Corporation | $170.50 | 2023-2025 | Kisqali |
| Astrazeneca Pharmaceuticals LP | $140.88 | 2022-2024 | Calquence, Lynparza |
| Pfizer INC. | $124.17 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $95.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $82.97 | 2024-2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $56.28 | 2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $49.50 | 2022-2023 | Brukinsa |
| Emd Serono, INC. | $44.37 | 2023 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $44.21 | 2023-2024 | Onivyde, Tazverik |
| Geron Corporation | $41.86 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $41.18 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.81 | 2025 | Iclusig |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $34.49 | 2022-2023 | Libtayo |
| Celgene Corporation | $34.44 | 2022-2024 | Reblozyl |
| Mirati Therapeutics, INC. | $30.79 | 2023-2024 | Krazati |
| Adaptive Biotechnologies Corporation | $30.00 | 2025 | Clonoseq |
| Genzyme Corporation | $29.26 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $29.18 | 2023 | Keytruda |
| Genmab U.S., INC. | $23.55 | 2024 | Tivdak |
| Progenics Pharmaceuticals, INC. | $23.11 | 2024 | |
| Array Biopharma INC | $22.72 | 2024 | Mektovi, Tukysa, Braftovi |
| Daiichi Sankyo INC. | $22.54 | 2024 | Enhertu |
| Pharmacosmos Therapeutics INC. | $21.37 | 2023 | Monoferric |
| Acrotech Biopharma INC. | $20.59 | 2024 | Beleodaq |
| Rigel Pharmaceuticals, INC. | $19.87 | 2024 | Rezlidhia, Tavalisse |
| Lilly USA, LLC | $19.34 | 2023 | Retevmo, Jaypirca |
| Tersera Therapeutics LLC | $18.88 | 2023 | Zoladex |
| Abbvie INC. | $18.35 | 2024 | |
| Karyopharm Therapeutics INC. | $18.32 | 2022 | |
| Pharmaand Gmbh | $18.27 | 2025 | Rubraca |
| Tolmar, INC. | $18.27 | 2025 | Rubraca |
| Pharmaessentia USA Corporation | $17.65 | 2023 | Besremi |
| Incyte Corporation | $16.64 | 2023 | Jakafi |
| Sobi, INC | $16.15 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $15.97 | 2022 | |
| Kyowa Kirin, INC. | $15.71 | 2022 | |
| Morphosys, US INC. | $14.32 | 2023 | Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Bywaters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.